Neurocrine Biosciences, Inc. (NBIX) Q4 2013 Earnings Results

Neurocrine Biosciences Misses on Revenue, Stock Down 2.72%

Neurocrine Biosciences reported a loss of $0.16 per share, which was slightly better than expected. However, the lack of revenue data and no guidance update contributed to a 2.72% drop in stock price. Investors may be concerned about the company's future performance without clearer direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.16	N/A	+6.43%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed a cautious optimism regarding the future, emphasizing their focus on pipeline advancements. They highlighted ongoing commitments to innovation.

We are focused on advancing our pipeline and are optimistic about future opportunities.

Our commitment to innovation remains strong despite current challenges.

Neurocrine Biosciences Misses on Revenue, Stock Down 2.72%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on Revenue, Stock Down 2.72%

Key numbers

Management commentary